Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
Additional analysis from the NIAGARA study were presented
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.